Deepal Dalal, DPM
Foot & Ankle Surgery · Burbank, CANPI 1164927257
Payments from drug & device makers
Across 86 payments — averaging $92.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Arthrex$3K
- Saxum Surgical, Inc.$2K
- Evolution Surgical, Inc$1K
- Treace Medical Concepts, Inc.$1K
- Stryker$373
- Johnson & Johnson$176
- plus $399 from 12 others
What the payments were for
- Travel & lodging$3,60345%
- Food & beverage$3,07639%
- Education$1,26116%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Arthrex | 34 | $3,041 |
| Saxum Surgical, Inc. | 11 | $1,547 |
| Evolution Surgical, Inc | 3 | $1,262 |
| Treace Medical Concepts, Inc. | 5 | $1,141 |
| Stryker | 10 | $373 |
| Johnson & Johnson(2 entities) | 6 | $176 |
| Paratek Pharmaceuticals, Inc. | 4 | $82 |
| Orthofix Medical, Inc. | 2 | $50 |
| Kerecis Limited | 1 | $33 |
| Organogenesis Inc. | 1 | $33 |
| Paragon 28, Inc. | 2 | $31 |
| Bioventus LLC | 1 | $28 |
| LEO Pharma Inc. | 1 | $27 |
| Sun Pharmaceutical Industries Inc. | 1 | $26 |
| Polynovo North America LLC | 1 | $23 |
| Melinta Therapeutics, LLC | 1 | $22 |
| Mallinckrodt Hospital Products Inc. | 1 | $22 |
| Smith+Nephew | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Lapiplasty System$1,017
- PROPHECY$143
How this compares
$7,940 in reported general payments places this provider in the 80th percentile of 1,126 foot & ankle surgery providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ketoconazole | 199 | $4,940 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 29 | $664 |
| Terbinafine Hcl | 32 | $326 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 15 | $133 |
| Ammonium Lactate | 15 | $123 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 20 | $108 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 19 | $91 |
| Ibuprofen | 13 | $71 |
| Gabapentin | 12 | $25 |
| Meloxicam | 12 | $10 |
Paid to pharmacies, not to this prescriber.
Other foot & ankle surgery in Burbank
- Joseph ParkBurbank$387K
- Martina RandallBurbank$144K
- Armen HagopjanianBurbank$94K
- Mark MikhaelBurbank$68K
- John ZimmermanBakersfield$4.6M
- Eric GizaSacramento$3.7M
- Thomas HarrisPasadena$3M
- Felix SigalLos Angeles$2.2M
- Thomas ChangSanta Rosa$2.1M
- Michael CoughlinSan Francisco$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.